Persevere Therapeutics headquarters details
- Street address
- 1055 Westlakes Dr Suite 300
- City
- Berwyn
- State / region
- Pennsylvania
- ZIP / postal code
- 19312
- Country
- United States
- Phone
- +1 610 922 1910
- Founded
- 2021
- linkedin.com/company/perseveretx
Location map
Open in Google MapsAll Persevere Therapeutics office locations
| City | State / region | Country | Type |
|---|---|---|---|
| Berwyn HQ | Pennsylvania | United States | Headquarters |
About Persevere Therapeutics
Persevere Therapeutics is headquartered in Berwyn, Pennsylvania, United States. Founded in 2021, the company employs approximately 32 people worldwide.
Where is Persevere Therapeutics's main office?
Persevere Therapeutics's main headquarters office is located at 1055 Westlakes Dr Suite 300, Berwyn, Pennsylvania 19312, United States. This is the company's primary corporate address.
Persevere Therapeutics contact information
The main switchboard for Persevere Therapeutics headquarters can be reached at +1 610 922 1910. Official website: perseveretherapeutics.com/panavance-is-now-persevere.
What does Persevere Therapeutics do?
Persevere Therapeutics is a clinical-stage pharmaceutical company that advances the development of GP-2250 novel oncology therapeutics focused on improving the effectiveness of cancer treatments.
Frequently asked questions
Where is Persevere Therapeutics headquarters?
Persevere Therapeutics's headquarters is located at 1055 Westlakes Dr Suite 300, Berwyn, Pennsylvania 19312, United States.
What is Persevere Therapeutics's corporate address?
The corporate headquarters address is 1055 Westlakes Dr Suite 300, Berwyn, Pennsylvania 19312, United States.
When was Persevere Therapeutics founded?
Persevere Therapeutics was founded in 2021 and employs approximately 32 people.
What is Persevere Therapeutics's phone number?
The main phone number for Persevere Therapeutics headquarters is +1 610 922 1910.
How many employees does Persevere Therapeutics have?
Persevere Therapeutics has approximately 32 employees (GraphIQ estimate, 2026).